Évaluation de la survie et de la progression de la maladie des patients diagnostiqués avec un sarcome métastatique des tissus mous traité par chimiothérapie palliative
High-grade sarcomas present a metastatic progression in approximately 50% of cases. The effectiveness of palliative chemotherapy as a treatment of systemic metastases is still modest. The main objective of this study is to assess disease progression and survival of patients diagnosed with metastatic soft tissue sarcomas treated with palliative chemotherapy. A retrospective chart review of 68 patients treated with palliative chemotherapy for metastatic soft tissue sarcomas between 2003 and 2013 at Maisonneuve-Rosemont Hospital was achieved. Data for control group of 36 patients with metastatic soft tissue sarcomas not treated with chemotherapy was collected retrospectively. Median overall survival with chemotherapy treatments was more than two times overall survival without treatments, which were 20 months and 7 months, respectively (p=0.0001). Overall survival was improved for all histologic subtypes with chemotherapy treatments, especially for leiomyosarcomas and synovial sarcomas, even though the difference in survival was not statistically significant between treated and untreated groups. When chemotherapy was given in combined therapy during first line of treatment, event-free survival was statistically longer (p=0.0184) and favorable responses rates were doubled. In conclusion, results have shown a significantly improved overall survival in all histological groups with chemotherapy treatments. Nevertheless, patients with favorable response to chemotherapy have poor outcomes. Additional treatment options are needed.
Palliative Soft-tissue sarcomas Metastasis Chemotherapy Survival